C11 ACETATE PET IMAGING OF PROSTATE AND RENAL CANCER

前列腺癌和肾癌的 C11 醋酸盐 PET 成像

• 批准号: 6514857
• 负责人: SCOTT E SNYDER
• 金额: $ 31.33万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-04-01 至 2004-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6514857
• 关键词: HMG coA reductases; acetates; acetyl coA carboxylase; adenocarcinoma; athymic mouse; carbon; cell line; clinical research; diagnosis design /evaluation; fatty acid synthase; human subject; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; pancreas neoplasms; pharmacokinetics; positron emission tomography; prostate neoplasms; radionuclides; renal cell carcinoma; small cell lung cancer

DESCRIPTION: (Adapted from PI's Summary) There is a need for new approaches to metabolic imaging of prostate and renal cancer. Positron emission tomography (PET) allows for cross sectional metabolic imaging, and is now emerging as an important clinical diagnostic imaging modality. PET imaging of glycolytic metabolism using the tracer fluorodeoxyglucose has proven useful in the diagnosis and staging of several malignancies, but has shown limited value in renal and prostate cancer. Positron radiotracers depicting metabolic pathways other than glycolytic metabolism are needed to fully develop the potential of PET in oncology. Carbon-11 acetate is a potential radiotracer for the depiction of the altered intermediary metabolism in malignant neoplasms. The purpose of this research is to understand the participating metabolic pathways responsible for the high uptake and retention of acetate radiotracer observed on PET imaging in certain malignant neoplasms, most notably renal cell carcinoma and prostate cancer. Acetate is a central molecule of intermediary metabolism with access to both catabolic and anabolic pathways. In this proposed research, the participating metabolic pathways and intermediate pools of acetate radiotracer will be investigated in vitro using cell culture and animal models of selected malignant neoplasms and tissue culture of pools will be correlated with measurements of the expression of enzymes involved in intermediary and anabolic lipid metabolism of acetate to understand the rate limiting steps and dominant tracer pools responsible for the uptake and retention of radiotracer acetate in certain malignancies. Kinetics of carbon-11 acetate on PET imaging of human subjects with prostate cancer and renal cancer prior to resection, and on micro PET imaging of athymic mice bearing xenographs of selected malignancies will be analyzed and compared to enzyme measurement of these tissues in vitro to determine the role of transport and intermediary metabolism enzyme expression in the tracer kinetics of renal and prostate cancer. The carbon-11 acetate imaging of human subjects with prostate cancer and renal cell carcinoma involved in this study will also be compared with surgical and histopathological findings to assess diagnostic accuracy in clinical diagnosis.

描述：（改编自PI总结）需要新的方法， 前列腺癌和肾癌的代谢成像。正电子发射断层扫描 (PET)允许横截面代谢成像，现在正成为一种新兴的 重要的临床诊断成像模式。糖酵解PET显像 使用示踪剂氟脱氧葡萄糖的代谢已被证明可用于 诊断和分期的几种恶性肿瘤，但已显示出有限的价值， 肾癌和前列腺癌。描述代谢途径的正电子放射性示踪剂 除了糖酵解代谢之外，还需要充分发挥 PET在肿瘤学中的应用碳-11醋酸盐是一种潜在的放射性示踪剂， 恶性肿瘤中间代谢的改变。的目的 这项研究是为了了解参与代谢途径负责 对于PET上观察到的乙酸盐放射性示踪剂的高吸收和保留 在某些恶性肿瘤，最明显的是肾细胞癌， 前列腺癌醋酸盐是中间代谢的中心分子， 进入分解代谢和合成代谢途径。在这项研究中， 乙酸盐放射性示踪剂的参与代谢途径和中间池 将在体外使用细胞培养和动物模型进行研究， 恶性肿瘤和组织培养池将与 参与中间和合成代谢的酶的表达的测量 脂代谢的乙酸酯，以了解限速步骤和主导 示踪剂池负责吸收和保留放射性示踪剂醋酸盐， 某些恶性肿瘤醋酸碳-11对人体PET成像的动力学 切除前患有前列腺癌和肾癌的受试者， 将对携带选定恶性肿瘤异种移植物的无胸腺小鼠进行PET成像。 分析并与体外这些组织的酶测量进行比较， 确定转运和中间代谢酶表达的作用 肾脏和前列腺癌的示踪动力学。碳-11醋酸盐 患有前列腺癌和肾细胞癌的人类受试者的成像 参与这项研究的患者也将与手术和 组织病理学结果，以评估临床诊断的准确性。